Raymond James Lowers DexCom (NASDAQ:DXCM) Price Target to $99.00

DexCom (NASDAQ:DXCM) had its price target dropped by stock analysts at Raymond James from $115.00 to $99.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “strong-buy” rating on the medical device company’s stock. Raymond James’ price objective suggests a potential upside of 32.18% from the company’s current price.

Several other analysts also recently weighed in on DXCM. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Saturday, October 12th. Canaccord Genuity Group restated a “buy” rating and issued a $145.00 price target on shares of DexCom in a report on Tuesday, July 23rd. BTIG Research dropped their price objective on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Barclays reduced their price objective on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research note on Monday, July 29th. Finally, Wells Fargo & Company boosted their price target on DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday. Seven research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $105.75.

DexCom Trading Up 0.1 %

Shares of DXCM traded up $0.05 during trading hours on Friday, reaching $74.90. 9,605,399 shares of the company traded hands, compared to its average volume of 3,881,020. The firm has a market cap of $29.79 billion, a price-to-earnings ratio of 48.32, a PEG ratio of 2.16 and a beta of 1.18. DexCom has a 12-month low of $62.34 and a 12-month high of $142.00. The stock’s fifty day moving average price is $70.13 and its 200 day moving average price is $98.71. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, October 24th. The medical device company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. The business had revenue of $994.20 million for the quarter, compared to the consensus estimate of $991.55 million. DexCom had a net margin of 16.95% and a return on equity of 31.41%. Sell-side analysts forecast that DexCom will post 1.69 earnings per share for the current year.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,824 shares of company stock valued at $126,390. 0.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of DXCM. Team Hewins LLC increased its holdings in DexCom by 3.4% in the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock valued at $354,000 after buying an additional 83 shares during the last quarter. Bleakley Financial Group LLC increased its holdings in shares of DexCom by 1.3% in the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after acquiring an additional 87 shares during the last quarter. Capital Insight Partners LLC increased its holdings in shares of DexCom by 2.5% in the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock valued at $418,000 after acquiring an additional 90 shares during the last quarter. HM Payson & Co. raised its position in shares of DexCom by 6.0% during the 1st quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock worth $247,000 after acquiring an additional 100 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its stake in DexCom by 0.3% during the first quarter. State of Alaska Department of Revenue now owns 41,830 shares of the medical device company’s stock worth $5,801,000 after purchasing an additional 105 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.